Successful application of eculizumab in typical haemolytic uraemic syndrome
A woman in her 40s with no medical history presented on hospital day #0 with 3 days of epigastric pain, nausea, vomiting and bloody diarrhoea. Initial blood work demonstrated acute kidney injury with metabolic acidosis with an elevated anion gap, thrombocytopenia, an elevated lactate dehydrogenase, and an undetectable haptoglobin. She was quickly diagnosed with haemolytic uraemic syndrome from Shiga toxin-producing O157:H7 <i>Escherichia coli</i> Her microangiopathic haemolytic anaemia and renal failure progressively worsened and only improved after the initiation of eculizumab, a monoclonal antibody directed against complement component C5. We report a case of Shiga toxin-producing <i>E. coli</i>-haemolytic uraemia syndrome with a complement-mediated component.
Authors
- Lisa Lee (ORCID: https://orcid.org/0000-0001-5857-9260)
- Garo Hagopian
- Minh‐Ha Tran (ORCID: https://orcid.org/0000-0002-9974-5277)
- Omid Yazdanpanah (ORCID: https://orcid.org/0000-0002-5795-461X)
Institutions
- University of California, Irvine Medical Center (US)
Publication Details
- Journal
- BMJ Case Reports
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1136/bcr-2023-256449
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00